Cancer in Transgender and Gender-Diverse Persons

Author:

Leone Alberto Giovanni1,Trapani Dario23,Schabath Matthew B.4,Safer Joshua D.56,Scout N. F. N.7,Lambertini Matteo89,Berardi Rossana10,Marsoni Silvia11,Perrone Francesco12,Cinieri Saverio13,Miceli Rosalba1,Morano Federica1,Pietrantonio Filippo1

Affiliation:

1. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

2. European Institute of Oncology, IRCCS, Milan, Italy

3. Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts

4. H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

5. Division of Endocrinology, Icahn School of Medicine at Mount Sinai, New York, New York

6. Mount Sinai Center for Transgender Medicine and Surgery, New York, New York

7. National LGBT Cancer Network, Providence, Rhode Island

8. Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genova, Genova, Italy

9. Department of Medical Oncology, Unità Operativa Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy

10. Oncology Clinic, Università Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italy

11. IFOM, FIRC Institute of Molecular Oncology, Milan, Italy

12. Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy

13. Medical Oncology Unit, Ospedale di Summa A. Perrino, Brindisi, Italy

Abstract

ImportanceTransgender and gender-diverse individuals face unique challenges, including barriers to health care access and inequities in treatment, that may influence cancer risk and outcomes.ObservationsIn this narrative review, a scoping review was conducted focusing on primary and secondary prevention and epidemiology of cancer, barriers to health care services, and health care practitioners’ knowledge about specific issues pertaining to transgender and gender-diverse individuals. PubMed, the Cochrane Library, and Embase, were reviewed for citations from their inception to December 31, 2021. This review revealed that transgender and gender-diverse people had a high prevalence of tobacco consumption and alcohol use and high rates of infection with human papillomavirus (HPV) and HIV. Transgender and gender-diverse individuals were less likely to adhere to cancer screening programs and had a higher incidence of HIV- and HPV-associated cancers. Social and economic determinants seemed to drive these disparities in risk factors and outcomes. A lack of knowledge about gender minorities’ health needs among health care practitioners was evidenced, and it represented a major hurdle to cancer prevention, care, and survivorship for transgender and gender-diverse individuals. Discrimination, discomfort caused by gender-labeled oncological services, stigma, and lack of cultural sensitivity of health care practitioners were other barriers met by transgender and gender-diverse persons in the oncology setting.Conclusions and RelevanceThe findings suggest that transgender and gender-diverse peoples’ needs in the cancer care continuum are not optimally addressed. Effective solutions are needed to offer the best care to every patient in a person-centric and gender diversity–sensitive environment.

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 37 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3